Treatments, cost and healthcare utilization of patients with segmental bone defects
•Treatment of large bone defects is associated with significant complication rates, especially for patients with osteomyelitis.•Amputation rates reach 14.5% in patients with bone defects due to osteomyelitis at the 2-year follow-up time point.•Comparisons of hospital costs to payments highlights min...
Gespeichert in:
Veröffentlicht in: | Injury 2021-10, Vol.52 (10), p.2935-2940 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Treatment of large bone defects is associated with significant complication rates, especially for patients with osteomyelitis.•Amputation rates reach 14.5% in patients with bone defects due to osteomyelitis at the 2-year follow-up time point.•Comparisons of hospital costs to payments highlights minimal margins, suggesting potential financial uncertainty facing hospitals providing care for affected patients.
Treatment of large segmental defects in skeletal long bones is challenging. Heterogeneity in patient presentation further increase the difficulty in designing and running randomized trials, hence the paucity of published data with large patient numbers. This study was designed to help understand patient presentation, costs and outcomes, using real world data sources.
Two data sources (Premier healthcare database (PHD) and IBM® MarketScan® Commercial Claims and Medicaid databases) were utilized, PHD for intraoperative and cost analyses, MarketScan for payer costs and longitudinal (2-year) outcomes. Patients were included in the analysis if they had diagnoses of osteomyelitis, non-union or open (acute) fractures, treated with bone graft and/or spacers, using either the Masquelet or external frames. Patient cohorts were defined by diagnosis at index (acute fracture, osteomyelitis, non-union) and descriptive statistics were conducted for patient variables (demographic, comorbidities) and outcomes. Risk of complications were estimated using logistic regression models. Hospital and payer costs for index and follow-up periods, were estimated using least means square estimators from generalized linear model outputs. All costs and payments were adjusted for inflation to 2019 consumer price-index.
904 patients were identified in PHD (414 fractures, 388 osteomyelitis and 102 nonunion patients). Main comorbidities at time of initial surgery were hypertension (32.7%) followed by obesity (22.1%), diabetes with complications (20.9%) and chronic pulmonary disease (20.6%). Significant variability in surgical operating room time and length of stay were observed, with averages of 484.7 minutes and 11.7 days, respectively. Two-year postoperative infection rates ranged from 33.1% - 58.5%, the highest infection rates being reflective of ongoing infections in patients initially treated for osteomyelitis. Amputation rates ranged from 10.0% in patients with bone loss due to acute factures to 14.5% in patients with osteomyelitis. Osteomyelitis patients were also the costliest, |
---|---|
ISSN: | 0020-1383 1879-0267 |
DOI: | 10.1016/j.injury.2021.01.016 |